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Zusammenfassung
Hintergrund: Mit der Mammaszintigraphie steht ein
Verfahren zur Diagnostik der Brustdrüsenerkrankungen
zur Verfügung, welches sich aufgrund der Limitationen
bei der Detektion kleiner Mammakarzinome bislang
nicht in der klinischen Routine durchsetzen konnte. Ziel
der Arbeit ist es, den Wert des Verfahrens bei der Beur-
teilung der Wirkung einer neoadjuvanten Chemothera-
pie von Mammakarzinomen zu überprüfen. Material und
Methoden: Dazu wurden bei 9 Patientinnen insgesamt
36 Mammaszintigramme vor, während und nach neoad-
juvanter Chemotherapie angefertigt und das Speicher-
verhalten des eingesetzten Radiopharmazeutikums 
Tc-99m Sestamibi (740 MBq) mit dem histopathologisch
verifizierten Tumoransprechen korreliert. Ergebnisse: Bei
den zum Therapiemonitoring durchgeführten Untersu-
chungen wurde im Falle einer Vollremission (n = 3) be-
reits nach dem 1. Zyklus eine rückläufige Speicherinten-
sität beobachtet, die sich im weiteren Verlauf vollständig
normalisierte. Bei partiellem Tumorresponse (n = 3) war
eine nach 2 Therapiezyklen vergleichsweise geringere
Abnahme der Speicherintensität mit Persistenz bis zur
Operation vorhanden. Bei fehlendem Tumoransprechen
(n = 3) blieb die Mehrspeicherung im Verlauf konstant
hoch. Schlussfolgerungen: Die vorliegenden vorläufigen
Daten weisen darauf hin, daß die Mammaszintigraphie
geeignet zu sein scheint, bereits frühzeitig das Tumor-
ansprechen auf eine neoadjuvante Chemotherapie zu
beurteilen. 
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Summary
Background: Aim of the study was to assess the value of
scintimammography using Tc-99m sestamibi in the eval-
uation of tumor response to neoadjuvant chemotherapy.
Material and Methods: Results were calculated for 9 pa-
tients undergoing neoadjuvant chemotherapy. Scinti-
mammography using 740 MBq Tc-99m sestamibi was
performed before, during and after chemotherapy, and
sestamibi uptake was scored visually and semiquanti-
tatively to evaluate tumor response. Results: In the case
of complete response (n = 3) sestamibi uptake decreased
8 days after beginning neoadjuvant chemotherapy and
normalized in the following course. Focal uptake de-
creased more slowly in patients with partial response 
(n = 3), who showed clear, persisting tracer accumula-
tion after therapy. The patients without response (n = 3)
showed a persisting high tumor activity even after
chemotherapy was completed. Conclusions: The prelim-
inary data suggest that in contrast to other imaging
modalities scintimammography appears to yield early
information regarding tumor response to neoadjuvant
chemotherapy. 
Breast Cancer: Monitoring Response to 
Neoadjuvant Chemotherapy Using Tc-99m Sestamibi
Scintimammography 
R. Tilinga M. Keßlerb M. Untchc H. Sommerd R. Linkea K. Brinkbäumera K. Hahna
a Klinik für Nuklearmedizin, 
b Institut für Klinische Radiologie, 
c Klinik für Frauenheilkunde, Großhadern, 
dUniversitäts-Frauenklinik, Innenstadt, Ludwig-Maximilians-Universität München, Germany
28 Onkologie 2003;26:27–31 Tiling/Keßler/Untch/Sommer/Linke/
Brinkbäumer/Hahn
Introduction
The first results for scintimammography using Tc-99m ses-
tamibi published between 1994 and 1996 [1–7] were very en-
couraging with a reported sensitivity of 84–96% and a speci-
ficity of 86–100%. The subsequent publication of two multi-
center studies and other targeted investigations, however, led
to revision of these optimistic expectations [8–11]. The unsat-
isfactory delineation of small invasive carcinomas and in-situ-
tumors have shown to be the major limitations of scintimam-
mography. Since the detection of small tumors plays a subor-
dinate role in this particular use, the objective of the present
study was to define its role in the evaluation of tumor re-
sponse in neoadjuvant chemotherapy.
Patients and Methods
Scintimammographic evaluation of tumor response was performed in pa-
tients with confirmed carcinomas undergoing neoadjuvant chemotherapy
(epirubicin/paclitaxel). The 9 women underwent 4 scintimammographic
examinations each (total 36 examinations) according to the following
schedule: prior to therapy, following the first and second therapy cycle
(days 8–10 and days 28–30, respectively), and then preoperatively follow-
ing completion of chemotherapy. 
At clinical examination prior to neoadjuvant chemotherapy, all patients
exhibited palpable lesions. Previously performed mammography was typ-
ical or suspicious for malignancy in all cases. 2 patients additionally un-
derwent magnetic resonance imaging (MRI) with findings rated as defi-
nitely malignant. The tumor size estimated clinically or mammographical-
ly was larger than 3 cm. Before the women entered the study, malignancy
was proven histopatholocically after performing core biopsy.
Prior to scintigraphy, Tc-99m sestamibi (740 MBq) was injected into a cu-
bital vein of the arm contralateral to the breast with the suspected abnor-
mality. 5 min subsequent to injection, planar lateral scintimammograms
of the breasts were acquired using a double- or triple-head gamma cam-
era. Patients were examined in prone position with raised arms, the acqui-
sition time was 10 min for each breast. 
At visual interpretation of the images, areas of focally increased tracer
uptake of any intensity were considered suspicious, as were irregular or
confluent areas of increased uptake insofar as they exhibited high intensi-
ties and the contralateral breast exhibited normal uptake patterns.
For the evaluation of tumor response to neoadjuvant chemotherapy, up-
take patterns of the tumor or breast were assigned to one of four classes
based on visual criteria: significant (+++, higher than uptake in lung tissue
visualized on the same image), moderate (++, comparable to uptake in
the lung), slight (+, lower than uptake in the lung) or normal (0, no differ-
ence to surrounding glandular parenchyma). In addition, semiquantita-
tive evaluation of uptake intensity was performed. This was done at the
baseline examination and consisted in imposition of an irregular region of
interest (ROI) on the area of increased uptake representing the malig-
nancy and on a reference region of normal tracer uptake in the glandular
parenchyma of the ipsilateral breast. The count rates were then compared
and a tumor-to-background ratio (R) was calculated. The size of the re-
spective ROIs remained constant during the subsequent examinations in
each patient.
Tumor response was classified as follows:
– PCR, pathologically complete remission (no remaining invasive malig-
nant tissue confirmed at histopathology).
– CCR, clinically complete remission (total disappearance of tumor at
clinical examination, but histologic evidence of remaining invasive
residual tumor).
– PR, partial response (reduction in tumor size by more than one-half of
initial size).
– NC, no response (tumor reduction by less than one-half of initial size
or further tumor progression).
Results
All carcinomas in the patient group undergoing neoadjuvant
chemotherapy (n = 9) were initially characterized by a signifi-
cantly increased focal tracer uptake. 3 patients showed com-
Table 1. Visual und semiquantitative sestamibi-uptake before, during and after neoadjuvant chemotherapy related to tumor response
Patient Approximate Before After 1st cycle After 2nd cycle After Tumor size, Response
tumor size, chemotherapy (day 8–10) (day 26–30) chemotherapy cm 
   cm
R Visual R Visual R Visual R Visual
(histo-
(mammo- pathology)
graphy) 
1 3 2.3 +++ 1.9 ++ 1.0 + 0.9 0 0 PCR
2 5 2.7 +++ 2.0 ++ 1.0 + 1.0 0 0.3 CCR
3 6 1.9 +++ 1.7 +++ 1.0 + 1.0 0 0.3 CCR
4 4 1.8 +++ 1.8 +++ 1.4 ++ 1.2 + 1.9 PR
5 5 1.5 ++ 1.3 ++ 1.4 ++ 1.2 + 2.2 PR
6 4 2.5 +++ 2.2 +++ 1.3 ++ 1.1 + 1.8 PR
7 7 1.8 +++ 1.7 +++ 1.7 +++ 1.5 +++ 3.6 NC
8 5 1.6 +++ 1.5 +++ 1.5 +++ 1.5 +++ 4.0 NC
9 6 1.6 +++ 1.5 +++ 1.5 +++ 1.6 +++ 6 NC
R = Tumor : background ratio; visual = visual sestamibi-uptake; PCR = pathologically complete response; CCR = clinically complete response; 
PR = partial response; NC = no response.
+++ = significant; ++ = moderate; + = slight; 0 = normal.
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plete tumor remission as a result of neoadjuvant therapy. At
scintimammography carcinomas showed visual and semi-
quantitative evidence of declining tracer uptake after the first
therapy cycle (days 8–10). Following the second cycle, semi-
quantitative values had fallen to normal levels in all cases, al-
though visual interpretation revealed slight focal increased
uptake in 2 patients. Following completion of therapy, visual
and semiquantitative findings were normal in all cases (table
1, fig. 1). In 2 women with clinically complete remission, resid-
ual tumor was revealed at histopathology with diameters up
to 3 mm that escaped detection with scintimammography.
In 3 patients with partial response, scintimammography re-
vealed semiquantitative evidence of decreasing uptake inten-
sity after the first therapy cycle in 2 of 3 cases that did not per-
mit their differentiation from patients with complete re-
sponse. Following the second therapy cycle and again preop-
eratively, these patients, unlike those in the group with com-
plete remission, continued to exhibit both visual and semi-
quantitative evidence of detectable pathologic residual up-
take. 
The remaining 3 patients with either no response or reduction
in tumor size by less than 50% continued in all examinations,
including the preoperative session, to show both semiquanti-
tative and visual evidence of persisting increased sestamibi
uptake with at most a very discrete reduction in uptake inten-
sity.
Discussion
Scintimammography using Tc-99m sestamibi represents a
technique that does not depend on morphology but rather vi-
sualizes tumor metabolism expressed as a pathologic tracer
uptake. It had been postulated that the visualized uptake pat-
terns represent a perfusion-dependent accumulation of the
radiopharmaceutical in the tumor, following uptake of the
positively charged lipophilic complex by electrostatic interac-
tion with subsequent binding to negatively charged particles
in the cytosol and mitochondrial membrane [12]. Experiments
have compared the in vitro uptake of Tc-99m sestamibi of
normal cell cultures with that of malignant cells [13]. These
studies showed that the uptake of the radiopharmaceutical in
tumor cells was four times as high as in normal cells. If muscle
cells are excluded from the group of normal cells, the uptake
of sestamibi was nearly nine times as high as in normal cell
cultures.
An indication for scintimammography that has not yet been
extensively studied is its role in monitoring neoadjuvant
chemotherapy in advanced breast cancer. Investigations by
Maini et al. [14] and Mankoff et al. [15] have shown that, in
contrast to conventional protocols using clinical examination,
ultrasound and mammography, scintimammography is suit-
able for accurately documenting the response of patients’ tu-
mors to therapy. In our study group, response to therapy was
demonstrated as early as 8–10 days following the initiation of
chemotherapy in patients ultimately showing complete tumor
response as shown by a reduction in tracer uptake. Following
completion of the second therapy cycle, tracer uptake pat-
terns had approached normal limits and went on to complete
normalization at conclusion of chemotherapy. Residual tu-
mors measuring only a few millimeters, as expected, escaped
detection; thus, pre-operative differentiation between clini-
cally and histopathologically complete remission was not
possible.
In comparison, patients who ultimately exhibited only partial
response to chemotherapy showed a smaller, but still measur-
Fig. 1. Invasive breast carcinoma during neoadjuvant chemotherapy, scintimammography (planar lateral views). a) before chemotherapy, R = 1.9; b)
after the 1st cycle (day 10), R = 1.7; c) after the 2nd cycle (day 28), R = 1.0; d) preoperatively, R = 1.0. (R = tumor : background ratio.) Prior to neoad-
juvant chemotherapy, there is significant focal sestamibi uptake in the tumor. Following completion of the first chemotherapy cycle, there is significant
reduction in uptake intensity, followed by complete normalization during the patient’s subsequent clinical course. Histopathology revealed residual
invasive tumor (<3 mm) remaining from the tumor that had measured about 6 cm prior to chemotherapy; the residual tumor was not visualized at
scintimammography. R = tumor: background ratio
a b c d
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able decrease in uptake intensity after the second therapy cy-
cle. Significant residual uptake, however, was visualized at the
pre-operative examination. 
In non-responders, initial levels of tracer uptake generally re-
mained constant throughout chemotherapy. In individual cas-
es of slight decreases in tracer uptake, a definitive differentia-
tion between partial and non-response to chemotherapy was
not possible. This, however, was to be expected due to the de-
finition of the categories partial (>50% reduction in tumor
size) and non-response (<50% reduction in tumor size). 
Another study comparing scintimammography with positron
emission tomography (PET) showed that the intensity of Tc-
99m sestamibi uptake correlated exactly with the degree of
glucose metabolism. In fact, both methods returned analo-
gous results documenting tumor response after the second
therapy cycle at the latest [16].
Because of the expected increased importance of this thera-
peutic application in the future, the early evaluation of tumor
response to chemotherapy will become an ever greater chal-
lenge for diagnostic imaging. If future studies confirm the ca-
pabilities of nuclear medical methods in the early detection of
response or non-response to chemotherapy, findings of these
studies could exert decisive influence on patient management.
This application is one in which both conventional imaging
techniques and even MRI have significant limitations [17–21]. 
Feldman et al. [22] showed that nearly 50% of the patients
with clinically complete tumor response (CCR) exhibited
macroscopic residual disease, whereas 20% of the patients
with a clinically suggested partial remission (PR) had no
macroscopic tumor at surgery. Clinical examination often is
unable to differentiate a residual mass representing fibrosis
from a mass representing residual tumor. Similar problems
were found using mammography to evaluate tumor response.
Continuing presence of mammographic density and unchang-
ing microcalcification as a sign for malignancy have shown to
be the major reasons for the difficulties of mammography
[17–19, 22]. Maini et al. [14] described a sensitivity and speci-
ficity of mammography not exceeding 69 and 33%, respec-
tively. Ultrasound as an adjunct method has similar limita-
tions assessing tumor reponse, since even in case of complete
tumor response sonography cannot exclude residual tumor
mainly due to fibrosis [23].
Some better results have been reported for contrast-enhanced
MRI. Rieber et al. [21] found in the case of tumor response a
significant flattening of the Gd-DTPA uptake curve after the
first cycle of chemotherapy. After the forth cycle a complete
absence of Gd-DTPA uptake was observed. However, these
findings led to an underestimation of the extent of tumor in 2
patients and false negative findings in 4 patients. Gilles at al.
[24] demonstrated that the contrast behavior after administra-
tion of Gd-DTPA corresponds with the amount of residual
carcinoma, MRI findings could assess the histopathologic
proven disease extent in 83% in their series. 
Early information about the tumor response to neoadjuvant
chemotherapy could probably also be achieved using phos-
phorous-31 magnetic resonance spectroscopy (P-31 MRS).
Merchant et al. [25] showed that the different phospholipid
profiles correlate with specific histopathologic features like
cellular, granulocytic and lymphocytic infiltration, elastosis
and necrosis. These histologic features and molecules are
known to play important roles in cellular communication, reg-
ulation, and processes unique to malignant tissues. The find-
ings demonstrate the specificity of P-31 MRS to distinguish
between malignant, benign and noninvolved breast parenchy-
ma and between pathologic subsets of breast cancer [25–27].
For example, phosphomonoester metabolism was shown to be
altered in neoplastic tissues relative to the noninvolved tis-
sues, whereas phosphocreatine was elevated in benign tumors.
The tissue energy modulus indicated that benign tissue is rela-
tively more aerobic than noninvolved tissue and significantly
more aerobic than malignant tissue [26]. Localized P-31 MRS
performed sequentially before and during neoadjuvant
chemotherapy could probably assess early changes of tumor
biochemistry and contribute to monitoring tumor response in
this way. 
In conclusion, the limitations of scintimammography in de-
tecting small tumors play a subordinate role in the use of this
method for the evaluation of signs of response of carcinomas
to neoadjuvant chemotherapy. The findings of the present
study suggest that this may be an important new indication for
scintimammography. However, with respect to the very limit-
ed number of patients enrolled in this study, further examina-
tions will be necessary to define the role of this technique in
the future.
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